Progesterone Receptor (PR) belongs to a superfamily of nuclear hormone receptors. Estrogen Receptor (ER) induces PR expression, therefore, PR status serves as an indicator of an intact ER pathway. There are two known isoforms of PR; PR? and PRß. The current assays in clinical breast cancer measure both isoforms. PR is expressed in about 60-70% of invasive breast cancers. It is a weak prognostic factor by itself but a modest predictive factor that adds to the predictive value of ER for response to endocrine therapies, both in adjuvant and metastatic settings. The primary indication to assess PR in breast cancer is to predict response to hormonal therapies, such as tamoxifen, other selective estrogen receptor modulators (SERMs) and aromatase inhibitors.
KIT COMPONENTS (100 reactions)
- 50x DAB Chromogen 1 x 0.5ml
- Biotinylated goat anti-rabbit IgG(H+L) 1 x 15ml
- DAB substrate 1 x 15ml
- Hydrogen Peroxide Block 1 x 15ml
- Protein block 1 x 15ml
- Streptavidin Peroxidase 1 x 15ml
- Rabbit anti-human PgR
Store at +4°C. Please refer to protocols.
The products is “”FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES”””